Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers in the Sir William Dunn School of Pathology, together with colleagues from across Oxford, have successfully obtained a structure of the surface layer from Gram-negative bacteria, bound to the cell membrane via long sugars called lipopolysaccharide or endotoxin, by applying novel electron tomography techniques.

This proof-of-concept study shows how structural biology is entering a new era, where it is possible to resolve atomic structures directly inside their native environment in cells.

DunnCellpaper2.jpgGram-negative bacteria are widespread, and include several human pathogens, causing antibiotic resistant infections, which are difficult to treat. Most bacteria are surrounded by a protective surface layer made of proteins, termed ‘S-layer’. Due to their copy numbers on prokaryotes (bacteria and archaea), S-layer proteins are the most abundant class of proteins on earth. Despite their abundance and importance, atomic resolution details of S-layers are not available, and S-layers remain an under-explored area of fundamental biology.

This recent study by Tanmay Bharat’s group, in collaboration with Carol Robinson’s group in Department of Chemistry and Phillip Stansfeld’s group in Department of Biochemistry, shows the power of integrated structural biology in resolving atomic structures from cells, and deducing complex biological mechanisms in situ. In addition to the surface layer structure reported, this study reports the native structure and arrangement of endotoxin or lipopolysaccharide, which is a ubiquitous molecule in Gram-negative bacteria, including several human pathogens, as it is found on cells.

This study will have important implications not only in the field of prokaryotic biology related to S-layers, but also in the future of structure-based drug design.

Similar stories

Tamoxifen repurposing study shows no benefit in treating deadly fungal meningitis

Hopes that tamoxifen could improve survival for a deadly form of fungal meningitis have been dashed by the results of a clinical trial conducted by University of Oxford researchers and published today in eLife.

Oxford researchers awarded funding to complete community COVID-19 antiviral trial

Researchers from the Nuffield Department of Primary Care Health Sciences, University of Oxford, have today announced that they have been awarded funding through the National Institute for Health Research (NIHR) to work with several UK universities and carry out a first-of-its-kind clinical trial, testing novel antiviral COVID-19 treatments for use early on in the illness by people in the community with COVID-19 who are at higher risk of complications.

New therapeutic targets identified to treat inflammatory bowel disease

Millions of patients with ulcerative colitis or Crohn’s disease, collectively known as inflammatory bowel disease (IBD), are given fresh hope as a new study shows why some of them do not respond to current treatments.

Oxford researchers call for an urgent re-evaluation of “weak” opioid safety profile

A new study associates dispensation doses of tramadol with increased risk of mortality, cardiovascular events, and fractures compared to the use of codeine to treat pain.

Labelling proteins through the diet gives new insights into how collagen-rich tissues change as we age

A new study, published in eLife, uses advanced tissue analysis technology to show how the incorporation of new proteins changes in bone and cartilage with age.

Drug could help diabetic hearts recover after heart attack - Oxford research

Researchers at the University of Oxford have identified a drug that could ultimately help improve heart function in people with diabetes who have heart attacks.